Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Pipeline Includes Contact Lens That Delivers Drugs, AF Catheter

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's late-stage development projects include a combination product for eye allergies in Phase III trials

You may also be interested in...

Earnings Calls In Brief

Johnson & Johnson/Cordis: Sales of Cypher sirolimus-eluting coronary stents in the United States declined 44% from a year ago to $185 million in the third quarter, the firm reports Oct. 16. Internationally, sales of the device were off 40% to $190 million. The firm blamed reduced percutaneous coronary intervention procedure volumes, a decreased penetration rate for drug-eluting stents versus bare-metal stents, and burgeoning overseas competition. The drug-eluting stent market has declined by over 40% in the United States and over 10% internationally, J&J estimates. The firm believes its share of the U.S. market has been stable at about 46%, while international share of 37% was down from 51% a year ago. Worldwide, Cypher's market share is about 41%, the firm says. Overall, J&J's medical devices and diagnostics segment reported Q3 sales of $5.2 billion, up 6% from a year ago. Company-wide, the diversified drug and medical technology firm generated revenue of $15 billion, up 12.7% from a year ago

Underpenetrated U.S. Gastric Banding Market Has Room For Two

With Johnson & Johnson expected to launch its Realize adjustable gastric band in the United States by the end of the year, what physicians and analysts consider a highly underpenetrated market will finally have some competition

Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts